Shaping the future of diabetes care - Roche
Shaping the future of diabetes care - Roche
Shaping the future of diabetes care - Roche
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Proposed transaction structure<br />
r<br />
Effected through two consecutive but concurrent steps<br />
Disetronic<br />
Sales: 300 m CHF<br />
Infusion Systems<br />
Sales: 228 m CHF<br />
Injection Systems<br />
Sales: 72 m CHF<br />
Disetronic = 34 % or 0.66 million shares committed by major shareholder<br />
= 61 % or 1.18 million shares are publicly traded<br />
Step 1: Public tender <strong>of</strong>fer on 100 % <strong>of</strong> outstanding Disetronic shares<br />
CHF 670 for each Disetronic share = 1.84 million x 670 CHF 1 230 mm<br />
2 GS* per Disetronic Share = 3.7 million GS 350 mm<br />
Total Offer 1 580 mm<br />
Step 2: Sale <strong>of</strong> Injection business from Disetronic to Mr. Michel 420 mm<br />
Net Cost to <strong>Roche</strong> after consuming <strong>the</strong> tender <strong>of</strong>fer 1 160 mm<br />
* Assumes <strong>Roche</strong> Genussscheine (GS) at 95 CHF per share<br />
19
Change language